As of Friday close, Lifecore Biomedical Inc.’s (NASDAQ:LFCR) stock was down -$3.44, moving down -67.32 percent to $1.67. The average number of shares traded per day over the past five days has been 921,440 shares. 2 times new highs have been achieved over the past 5 days, with a -$2.91 fall in that time frame. In the last twenty days, the average volume was 317,675, while in the previous 50 days, it was 191,186.
Since last month, LFCR stock retreated -72.07%. Shares of the company fell to $1.52 on 03/17/23, the lowest level in the past month. A 52-week high of $11.95 was reached on 01/19/23 after having rallying from a 52-week low of $4.48. Since the beginning of this year, LFCR’s stock price has dropped by -74.23% or -$4.81, and marked a new high 4 times. However, the stock has declined by -86.03% since its 52-week high.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
LFCR stock investors should be aware that Lifecore Biomedical Inc. (LFCR) stock had its last reported insider trading activity 113 days ago on Nov 25. WYNNEFIELD PARTNERS SMALL CAP, the 10% Owner of the company, purchased of 345,260 shares for $7.97 on Nov 25. It resulted in a $2,751,722 investment by the insider. WYNNEFIELD PARTNERS SMALL CAP added 282,486 shares at an average price of $7.97 on Nov 25. The insider now owns 2,438,180 shares following the transaction.
The stock’s beta is 1.12. Besides these, the trailing price-to-sales (P/S) ratio of 0.28, the price-to-book (PB) ratio of 0.51.
In the three months ended November 29, Lifecore Biomedical Inc.’s quick ratio stood at 0.60, while its current ratio was 1.40, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending November 29 was 0.99, and the total debt-to-equity ratio was 1.47. On the profitability front, the trailing twelve-month gross margin is 24.40% percent. Based on annual data, LFCR earned $50.37 million in gross profit and brought in $185.79 million in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. LFCR’s revenue rose 100.0% to $43.36 million during the quarter, while net income inched up to $38.8 million. While analysts expected Lifecore Biomedical Inc. to report -$0.04 quarterly earnings, the actual figure was -$0.24 per share. During the quarter, the company generated -$5.03 million in EBITDA. The liabilities of Lifecore Biomedical Inc. were 204.91 million at the end of its most recent quarter ended November 29, and its total debt was $160.96 million. The value of shareholders’ equity is $30.32 million.
This quick technical analysis looks at Lifecore Biomedical Inc.’s (LFCR) price momentum. With a historical volatility rate of 551.59%, the RSI 9-day stood at 12.71% on 17 March.
With respect to its five-day moving average, the current Lifecore Biomedical Inc. price is down by -63.54% percent or -$2.91. At present, LFCR shares trade -72.03% below its 20-day simple moving average and -79.36% percent below its 100-day simple moving average. However, the stock is currently trading approximately -73.82% below its SMA50 and -82.42% below its SMA200.
Stochastic coefficient K was 25.51% and Stochastic coefficient D was 35.70%, while ATR was 0.73. Given the Stochastic reading of 3.34% for the 14-day period, the RSI (14) reading has been calculated as 15.37%. As of today, the MACD Oscillator reading stands at -0.73, while the 14-day reading stands at -1.07.
Lifecore Biomedical Inc. (LFCR) has been rated Buy by analysts. According to 0 brokerage firms, LFCR is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Lifecore Biomedical Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $10.00, the current consensus forecast for the stock is $10.00 – $10.00. Based on these forecasts, analysts predict Lifecore Biomedical Inc. (LFCR) will achieve an average price target of $10.00.